share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  2024/11/15 06:26

Moomoo AI 已提取核心訊息

Conduit Pharmaceuticals announced on November 12, 2024, that its previously issued unaudited financial statements for Q1 and Q2 2024 should no longer be relied upon. The restatement is necessary to correct the classification of deferred commission payable, which was incorrectly categorized as a long-term liability instead of a current liability.The reclassification affects the condensed consolidated balance sheets for the three months ended March 31, 2024, and the three and six months ended June 30, 2024. The company emphasized that this adjustment has no impact on its total liabilities for the affected periods. The company plans to address these changes through amendments to the respective Quarterly Reports on Form 10-Q.
Conduit Pharmaceuticals announced on November 12, 2024, that its previously issued unaudited financial statements for Q1 and Q2 2024 should no longer be relied upon. The restatement is necessary to correct the classification of deferred commission payable, which was incorrectly categorized as a long-term liability instead of a current liability.The reclassification affects the condensed consolidated balance sheets for the three months ended March 31, 2024, and the three and six months ended June 30, 2024. The company emphasized that this adjustment has no impact on its total liabilities for the affected periods. The company plans to address these changes through amendments to the respective Quarterly Reports on Form 10-Q.
Conduit Pharmaceuticals 於2024年11月12日宣佈,其之前發佈的2024年第一季度和第二季度未經審計的基本報表不再可靠。此次重述是爲了更正遞延佣金應付的分類,該項錯誤地被歸類爲長期負債而不是流動負債。此次重新分類影響到截至2024年3月31日的三個月和截至2024年6月30日的三個月及六個月的合併資產負債表。公司強調,此次調整不會影響受影響期間的總負債。公司計劃通過修訂相應的10-Q表季度報告來處理這些變更。
Conduit Pharmaceuticals 於2024年11月12日宣佈,其之前發佈的2024年第一季度和第二季度未經審計的基本報表不再可靠。此次重述是爲了更正遞延佣金應付的分類,該項錯誤地被歸類爲長期負債而不是流動負債。此次重新分類影響到截至2024年3月31日的三個月和截至2024年6月30日的三個月及六個月的合併資產負債表。公司強調,此次調整不會影響受影響期間的總負債。公司計劃通過修訂相應的10-Q表季度報告來處理這些變更。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息